skip to content
Primary navigation

Astagraf XL

Drug - Astagraf XL (tacrolimus) [Astellas Pharmaceuticals]

March 2014

Therapeutic area - Immunosuppresant

Approval criteria

  • Patient has received a kidney transplant AND
  • Patient has documented non-compliance with generic tacrolimus

Quantity limit

34 per 34 days


ASTAGRAF XL (tacrolimus extended-release capsules) is approved for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top